Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial

Ruhnke L, Röllig C, Herold S, Sauer T, Brandts CH, Steffen B, Schäfer-Eckart K, Krause S, Hänel M, Reichle A, Scholl S, Neubauer A, Mikesch JH, Schetelig J, Stölzel F, Kramer M, Haake A, Frimmel J, Krämer A, Schlenk R, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C, Aust D, Bornhäuser M, Ehninger G, Thiede C (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Haematologica

Book Volume: 108

Pages Range: 2520-2525

Journal Issue: 9

DOI: 10.3324/haematol.2022.281636

Authors with CRIS profile

Stefan Krause Medizinische Fakultät

Involved external institutions

Universitätsklinikum Carl Gustav Carus Dresden

Germany (DE) Ruprecht-Karls-Universität Heidelberg

Germany (DE) Universitätsklinikum Frankfurt am Main (KGU)

Germany (DE) Klinikum Chemnitz

Germany (DE) Universitätsklinikum Regensburg

Germany (DE) Universitätsklinikum Jena

Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM)

Germany (DE) Universitätsklinikum Münster

Germany (DE) Universitätsklinikum Leipzig

Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH)

Germany (DE)

How to cite

APA:

Ruhnke, L., Röllig, C., Herold, S., Sauer, T., Brandts, C.H., Steffen, B.,... Thiede, C. (2023). Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial. Haematologica, 108(9), 2520-2525. https://doi.org/10.3324/haematol.2022.281636

MLA:

Ruhnke, Leo, et al. "Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial." Haematologica 108.9 (2023): 2520-2525.

BibTeX: Download